According to a report by Hattori et al. analyzing 114 RA patients treated with adalimumab for 52 weeks or longer, the rate of improvement of the serum MMP-3 levels after 4 weeks was significantly lower in the DAS28-CRP remission group after 52 weeks than in the non-remission group. This evidence concerns the gene MMP3 and rheumatoid arthritis.